Lysosomal acid lipase and atherosclerosis

Hong Du, Gregory A. Grabowski

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Purpose of review: Atherosclerosis remains the leading cause of death in the developed countries. In addition to lipid-lowering drugs - statins, dietary control, and exercise, new approaches are needed for the treatment and prevention of atherosclerosis. This review will focus on the role(s) of lysosomal acid lipase and its use as an enzyme therapy to reduce atherosclerotic lesions in a mouse model and to examine the molecular basis supporting this novel strategy and its mechanism of effect. Recent findings: Administration of human lysosomal acid lipase via tail vein into mice with atherosclerosis eliminates early aortic and coronary ostial lesions and reduces lesional size in advanced disease. The reduction of advanced lesional area is related to decreases in foamy macrophages, collagen positive areas, and necrotic areas. Compared with sham-treated mice, the human lysosomal acid lipase-treated mice also have reduced levels of plasma cholesteryl esters, and reduced levels of hepatic cholesterol and triglycerides. Summary: These studies indicate that administrated lysosomal acid lipase affects the atherogenesis by at least two mechanisms: (1) direct targeting of lesional macrophages with resultant decreases in cholesteryl esters and triglyceride in the lysosomes of macrophages in the lesions; (2) systemic effects that mediate the liver to reduce the hepatic cholesteryl ester and triglyceride release, possibly leading to reduced production of VLDL and LDL.

Original languageEnglish (US)
Pages (from-to)539-544
Number of pages6
JournalCurrent Opinion in Lipidology
Volume15
Issue number5
DOIs
StatePublished - Oct 1 2004
Externally publishedYes

Fingerprint

Sterol Esterase
Cholesterol Esters
Macrophages
Atherosclerosis
Triglycerides
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Liver
Enzyme Therapy
Collagen
Lysosomes
Cholesterol
Developed Countries
Lipids
Plasmas
Tail
Cause of Death
Veins
Enzymes
Pharmaceutical Preparations
human LIPA protein

Keywords

  • Animal models
  • Cholesterol metabolism
  • Cholesteryl ester metabolism
  • Low-density lipoprotein receptor
  • Lysosomal storage disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lysosomal acid lipase and atherosclerosis. / Du, Hong; Grabowski, Gregory A.

In: Current Opinion in Lipidology, Vol. 15, No. 5, 01.10.2004, p. 539-544.

Research output: Contribution to journalReview article

Du, Hong ; Grabowski, Gregory A. / Lysosomal acid lipase and atherosclerosis. In: Current Opinion in Lipidology. 2004 ; Vol. 15, No. 5. pp. 539-544.
@article{8a8bae53988f4acb8d234766e35f8d9a,
title = "Lysosomal acid lipase and atherosclerosis",
abstract = "Purpose of review: Atherosclerosis remains the leading cause of death in the developed countries. In addition to lipid-lowering drugs - statins, dietary control, and exercise, new approaches are needed for the treatment and prevention of atherosclerosis. This review will focus on the role(s) of lysosomal acid lipase and its use as an enzyme therapy to reduce atherosclerotic lesions in a mouse model and to examine the molecular basis supporting this novel strategy and its mechanism of effect. Recent findings: Administration of human lysosomal acid lipase via tail vein into mice with atherosclerosis eliminates early aortic and coronary ostial lesions and reduces lesional size in advanced disease. The reduction of advanced lesional area is related to decreases in foamy macrophages, collagen positive areas, and necrotic areas. Compared with sham-treated mice, the human lysosomal acid lipase-treated mice also have reduced levels of plasma cholesteryl esters, and reduced levels of hepatic cholesterol and triglycerides. Summary: These studies indicate that administrated lysosomal acid lipase affects the atherogenesis by at least two mechanisms: (1) direct targeting of lesional macrophages with resultant decreases in cholesteryl esters and triglyceride in the lysosomes of macrophages in the lesions; (2) systemic effects that mediate the liver to reduce the hepatic cholesteryl ester and triglyceride release, possibly leading to reduced production of VLDL and LDL.",
keywords = "Animal models, Cholesterol metabolism, Cholesteryl ester metabolism, Low-density lipoprotein receptor, Lysosomal storage disease",
author = "Hong Du and Grabowski, {Gregory A.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1097/00041433-200410000-00007",
language = "English (US)",
volume = "15",
pages = "539--544",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Lysosomal acid lipase and atherosclerosis

AU - Du, Hong

AU - Grabowski, Gregory A.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Purpose of review: Atherosclerosis remains the leading cause of death in the developed countries. In addition to lipid-lowering drugs - statins, dietary control, and exercise, new approaches are needed for the treatment and prevention of atherosclerosis. This review will focus on the role(s) of lysosomal acid lipase and its use as an enzyme therapy to reduce atherosclerotic lesions in a mouse model and to examine the molecular basis supporting this novel strategy and its mechanism of effect. Recent findings: Administration of human lysosomal acid lipase via tail vein into mice with atherosclerosis eliminates early aortic and coronary ostial lesions and reduces lesional size in advanced disease. The reduction of advanced lesional area is related to decreases in foamy macrophages, collagen positive areas, and necrotic areas. Compared with sham-treated mice, the human lysosomal acid lipase-treated mice also have reduced levels of plasma cholesteryl esters, and reduced levels of hepatic cholesterol and triglycerides. Summary: These studies indicate that administrated lysosomal acid lipase affects the atherogenesis by at least two mechanisms: (1) direct targeting of lesional macrophages with resultant decreases in cholesteryl esters and triglyceride in the lysosomes of macrophages in the lesions; (2) systemic effects that mediate the liver to reduce the hepatic cholesteryl ester and triglyceride release, possibly leading to reduced production of VLDL and LDL.

AB - Purpose of review: Atherosclerosis remains the leading cause of death in the developed countries. In addition to lipid-lowering drugs - statins, dietary control, and exercise, new approaches are needed for the treatment and prevention of atherosclerosis. This review will focus on the role(s) of lysosomal acid lipase and its use as an enzyme therapy to reduce atherosclerotic lesions in a mouse model and to examine the molecular basis supporting this novel strategy and its mechanism of effect. Recent findings: Administration of human lysosomal acid lipase via tail vein into mice with atherosclerosis eliminates early aortic and coronary ostial lesions and reduces lesional size in advanced disease. The reduction of advanced lesional area is related to decreases in foamy macrophages, collagen positive areas, and necrotic areas. Compared with sham-treated mice, the human lysosomal acid lipase-treated mice also have reduced levels of plasma cholesteryl esters, and reduced levels of hepatic cholesterol and triglycerides. Summary: These studies indicate that administrated lysosomal acid lipase affects the atherogenesis by at least two mechanisms: (1) direct targeting of lesional macrophages with resultant decreases in cholesteryl esters and triglyceride in the lysosomes of macrophages in the lesions; (2) systemic effects that mediate the liver to reduce the hepatic cholesteryl ester and triglyceride release, possibly leading to reduced production of VLDL and LDL.

KW - Animal models

KW - Cholesterol metabolism

KW - Cholesteryl ester metabolism

KW - Low-density lipoprotein receptor

KW - Lysosomal storage disease

UR - http://www.scopus.com/inward/record.url?scp=5044222456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044222456&partnerID=8YFLogxK

U2 - 10.1097/00041433-200410000-00007

DO - 10.1097/00041433-200410000-00007

M3 - Review article

VL - 15

SP - 539

EP - 544

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 5

ER -